Plasma complement C3 levels are associated with insulin secretion independently of adiposity measures in non-diabetic individuals

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 25, Issue 5, 2015, Pages 510-517

  Fiorentino, T V ^a   Hribal, M L ^a   Andreozzi, F ^a   Perticone, M ^a   Sciacqua, A ^a   Perticone, F ^a   Sesti, G ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Complement C3; Complement system; Glucose homeostasis; Insulin secretion; Subclinical inflammation

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; C3 PROTEIN, HUMAN; INSULIN;

ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOMETABOLIC RISK; CONTROLLED STUDY; DIABETES MELLITUS; FAT MASS; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAJOR CLINICAL STUDY; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; WAIST CIRCUMFERENCE; ADULT; BLOOD; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE TOLERANCE TEST; IMMUNOLOGY; INSULIN RESISTANCE; ITALY; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; RISK FACTOR; SECRETION (PROCESS);

ADIPOSITY; ADULT; BODY MASS INDEX; COMPLEMENT C3; COMPLEMENT C4; CROSS-SECTIONAL STUDIES; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; ITALY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OVERWEIGHT; RISK FACTORS; WAIST CIRCUMFERENCE;

EID: 84927786118     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2015.02.007     Document Type: Article

References (30)

1. Schifferli J.A., Ng Y.C., Peters D.K. The role of complement and its receptor in the elimination of immune complexes. N Engl J Med 1986, 315:488-495.
2. Gabrielsson B.G., Johansson J.M., Lönn M., Jernås M., Olbers T., Peltonen M., et al. High expression of complement components in omental adipose tissue in obese men. Obes Res 2003, 11:699-708.
3. Rosen B.S., Cook K.S., Yaglom J., Groves D.L., Volanakis J.E., Damm D., et al. Adipsin and complement factor D activity: an immune-related defect in obesity. Science 1989, 244:1483-1487.
4. Baldo A., Sniderman A.D., St-Luce S., Avramoglu R.K., Maslowska M., Hoang B., et al. The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J Clin Invest 1993, 92:1543-1547.
5. Cianflone K., Roncari D.A.K., Maslowska M., Baldo A., Forden J., Sniderman A.D. Adipsin/acylation stimulating protein system in human adipocytes: regulation of triacylglycerol synthesis. Biochemistry 1994, 33:9489-9495.
6. Sniderman A.D., Cianflone K., Arner P., Summers L.K., Frayn K.N. The adipocyte, fatty acid trapping, and atherogenesis. Arterioscler Thromb Vasc Biol 1998, 18:147-151.
7. Germinario R., Sniderman A.D., Manuel S., Lefebvre S.P., Baldo A., Cianflone K. Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation stimulating protein. Metabolism 1993, 40:574-580.
8. Weyer C., Pratley R.E. Fasting and postprandial plasma concentrations of acylation-stimulation protein (ASP) in lean and obese pima Indians compared to Caucasians. Obes Res 1999, 7:444-452.
9. Weyer C., Tataranni P.A., Pratley R.E. Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration. Diabetes Care 2000, 23:779-785.
10. Muscari A., Massarelli G., Bastagli L., Poggiopollini G., Tomassetti V., Drago G., et al. Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. Eur Heart J 2000, 21:1081-1090.
11. Yang Y., Lu H.L., Zhang J., Yu H.Y., Wang H.W., Zhang M.X., et al. Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes. Int J Obes (Lond) 2006, 30:439-446.
12. Hernández-Mijares A., Jarabo-Bueno M.M., López-Ruiz A., Solá-Izquierdo E., Morillas-Ariño C., Martínez-Triguero M.L. Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors. Int J Obes (Lond) 2007, 31:927-932.
13. Xia Z., Cianflone K. Acylation-stimulating protein precursor proteins in adipose tissue in human obesity. Metabolism 2003, 52:1360-1366.
14. Samaras K., Botelho N.K., Chisholm D.J., Lord R.V. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obes (Silver Spring) 2010, 18:884-889.
15. Muscari A., Antonelli S., Bianchi G., Cavrini G., Dapporto S., Ligabue A., et al. Serum C3 is a stronger inflammatory marker of insulin resistance than C-reactive protein, leukocyte count, and erythrocyte sedimentation rate: comparison study in an elderly population. Diabetes Care 2007, 30:2362-2368.
16. Sesti G., Fiorentino T.V., Hribal M.L., Sciacqua A., Perticone F. Association of hepatic insulin resistance indexes to nonalcoholic fatty liver disease and related biomarkers. Nutr Metab Cardiovasc Dis 2013, 23:1182-1187.
17. Ajjan R., Grant P.J., Futers T.S., Brown J.M., Cymbalista C.M., Boothby M., et al. Complement C3 and C-reactive protein levels in patients with stable coronary artery disease. Thromb Haemost 2005, 94:1048-1053.
18. Engström G., Hedblad B., Eriksson K.F., Janzon L., Lindgarde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 2005, 54:570-575.
19. Muscari A., Bozzoli C., Puddu G.M., Sangiorgi Z., Dormi A., Rovinetti A., et al. Association of serum C3 levels with the risk of myocardial infarction. Am J Med 1995, 98:357-361.
20. Lo J.C., Ljubicic S., Leibiger B., Kern M., Leibiger I.B., Moede T., et al. Adipsin is an adipokine that improves β cell function in diabetes. Cell 2014, 158:41-53.
21. Ahrén B., Havel P.J., Pacini G., Cianflone K. Acylation stimulating protein stimulates insulin secretion. Int J Obes Relat Metab Disord 2003, 27:1037-1043.
22. Succurro E., Arturi F., Lugarà M., Grembiale A., Fiorentino T.V., Caruso V., et al. One-hour postload plasma glucose levels are associated with kidney dysfunction. Clin J Am Soc Nephrol 2010, 5:1922-1927.
23. Sesti G., Hribal M.L., Procopio T., Fiorentino T.V., Sciacqua A., Andreozzi F., et al. Low circulating insulin-like growth factor-1 levels are associated with high serum uric acid in nondiabetic adult subjects. Nutr Metab Cardiovasc Dis 2014, 24:1365-1372.
24. Marini M.A., Succurro E., Frontoni S., Arturi F., Sciacqua A., Hribal M.L., et al. Insulin sensitivity, β-cell function, and incretin effect in individuals with elevated 1-h postload plasma glucose levels. Diabetes Care 2012, 35:868-872.
25. Marini M.A., Frontoni S., Succurro E., Arturi F., Sciacqua A., Hribal M.L., et al. Insulin sensitivity, and β-cell function in relation to hemoglobin A1C. Nutr Metab Cardiovasc Dis 2014, 24:27-33.
26. Gutt M., Davis C.L., Spitzer S.B., Llabre M.M., Kumar M., Czarnecki E.M., et al. Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures. Diabetes Res Clin Pract 2000, 47:177-184.
27. Hanley A.J., Williams K., Gonzalez C., D'Agostino R.B., Wagenknecht L.E., Stern M.P., et al. San Antonio Heart Study, Mexico City Diabetes Study, Insulin Resistance Atherosclerosis Study. Prediction of type 2 diabetes using simple measures of insulin resistance: combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin resistance Atherosclerosis Study. Diabetes 2003, 52:463-469.
28. Stancakova A., Javorsky M., Kuulasmaa T., Haffner S.M., Kuusisto J., Laakso M. Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes 2009, 58:1212-1221.
29. Stumvoll M., Mitrakou A., Pimenta W., Jenssen T., Yki-Jarvinen H., Van Haeften I., et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000, 23:295-301.
30. Succurro E., Andreozzi F., Marini M.A., Lauro R., Hribal M.L., Perticone F., et al. Low plasma insulin-like growth factor-1 levels are associated with reduced insulin sensitivity and increased insulin secretion in nondiabetic subjects. Nutr Metab Cardiovasc Dis 2009, 19:713-719.